Siegfried Holding AG Share Price

Equities

SFZN

CH0014284498

Pharmaceuticals

Market Closed - Swiss Exchange 16:31:22 12/04/2024 BST 5-day change 1st Jan Change
887 CHF -1.11% Intraday chart for Siegfried Holding AG +0.23% +3.20%

Financials

Sales 2024 * 1.3B 1.42B 114B Sales 2025 * 1.42B 1.55B 125B Capitalization 3.8B 4.16B 334B
Net income 2024 * 148M 162M 13B Net income 2025 * 172M 188M 15.11B EV / Sales 2024 * 3.19 x
Net Debt 2024 * 351M 383M 30.82B Net Debt 2025 * 313M 343M 27.54B EV / Sales 2025 * 2.9 x
P/E ratio 2024 *
25.6 x
P/E ratio 2025 *
22 x
Employees 3,945
Yield 2024 *
0.43%
Yield 2025 *
0.46%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.11%
1 week+0.23%
Current month-3.69%
1 month-3.17%
3 months+2.01%
6 months+22.51%
Current year+3.20%
More quotes
1 week
877.00
Extreme 877
903.00
1 month
851.00
Extreme 851
936.00
Current year
827.00
Extreme 827
950.00
1 year
655.00
Extreme 655
950.00
3 years
566.00
Extreme 566
950.00
5 years
313.50
Extreme 313.5
950.00
10 years
136.20
Extreme 136.2
950.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 31/07/10
Director of Finance/CFO 53 30/04/17
Chief Tech/Sci/R&D Officer 56 31/03/19
Members of the board TitleAgeSince
Director/Board Member 55 31/12/15
Director/Board Member 63 31/12/13
Chairman 61 31/12/09
More insiders
Date Price Change Volume
12/04/24 887 -1.11% 3,865
11/04/24 897 +0.22% 3,170
10/04/24 895 +0.11% 3,710
09/04/24 894 +0.45% 3,374
08/04/24 890 +0.56% 3,966

Delayed Quote Swiss Exchange, April 12, 2024 at 04:31 pm

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
887 CHF
Average target price
1,016 CHF
Spread / Average Target
+14.53%
Consensus